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Abstract
Background: Angiogenesis is a fundamental process that allows tumor growth by providing
nutrients and oxygen to the tumor cells. Beyond the oxygen diffusion limit from a capillary blood
vessel, tumor cells become apoptotic. Angiogenesis results from a balance of pro- and anti-
angiogenic stimuli. Endogenous inhibitors regulate enzyme activities that promote angiogenesis.
Tumor cells may express pro-angiogenic factors and hydrolytic enzymes but also kinin-degrading
oligopeptidases which have been investigated.
Results: Angiogenesis induced by B16F10-Nex2 melanoma cells was studied in a co-culture with
HUVEC on Matrigel. A stimulating effect on angiogenesis was observed in the presence of B16F10-
Nex2 lysate and plasma membrane. In contrast, the B16F10-Nex2 culture supernatant inhibited
angiogenesis in a dose-dependent manner. This effect was abolished by the endo-oligopeptidase
inhibitor, JA-2. Thimet oligopeptidase (TOP) and neurolysin activities were then investigated in
B16F10-Nex2 melanoma cells aiming at gene sequencing, enzyme distribution and activity, influence
on tumor development, substrate specificity, hydrolytic products and susceptibility to inhibitors.
Fluorescence resonance energy transfer (FRET) peptides as well as neurotensin and bradykinin
were used as substrates. The hydrolytic activities in B16F10-Nex2 culture supernatant were totally
inhibited by o-phenanthrolin, JA-2 and partially by Pro-Ile. Leupeptin, PMSF, E-64, Z-Pro-Prolinal
and captopril failed to inhibit these hydrolytic activities. Genes encoding M3A enzymes in
melanoma cells were cloned and sequenced being highly similar to mouse genes. A decreased
proliferation of B16F10-Nex2 cells was observed in vitro with specific inhibitors of these
oligopeptidases. Active rTOP but not the inactive protein inhibited melanoma cell development in
vivo increasing significantly the survival of mice challenged with the tumor cells. On Matrigel, rTOP
inhibited the bradykinin – induced angiogenesis. A possible regulation of the homologous tumor
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Molecular Cancer 2007, 6:44 http://www.molecular-cancer.com/content/6/1/44enzyme in the perivascular microenvironment is suggested based on the observed rTOP inhibition
by an S-nitrosothiol NO donor.
Conclusion: Data show that melanoma cells secrete endo-oligopeptidases which have an
important role in tumor proliferation in vitro and in vivo. rTOP inhibited growth of subcutaneously
injected B16F10-Nex2 cells in mice. TOP from tumor cells and bradykinin in endothelial cells are
two antagonist factors that may control angiogenesis essential for melanoma growth. A regulatory
role of NO or S-nitrosothiols is suggested.
Background
Angiogenesis is a fundamental process in tumor growth,
providing nutrients and oxygen to the tumor cells. This
complex process involves extensive interplay between
cells, soluble factors and ECM components. Among the
soluble factors, secreted peptidases by tumor and neigh-
bor cells can have a significant role in both tumor devel-
opment and angiogenesis. Tumor cells express many
different types of proteases that are associated with tumor
invasibility [1]. Considering the various specificities of
secreted and membrane-bound hydrolytic enzymes in the
invasive melanoma a diversity of products can be gener-
ated. Peptide fragments can stimulate tumor cells to pro-
duce oligo-, amino- and carboxipeptidases for further
degradation giving rise either to biologically active pep-
tides (growth factors, regulators or signalling ligands), or
to substrates accessible to be used as nitrogen source.
Presently, we describe the stimulating effect of B16F10-
Nex2 melanoma cells on endothelial cells in a co-culture
model of angiogenesis on Matrigel in vitro. In contrast, an
inhibitory effect of melanoma cell culture supernatant
was observed. The agents responsible for these effects were
investigated.
We detected the expression of oligopeptidases in murine
melanoma cells of high invasiveness. The homologous
mammalian enzymes of the M3A subfamily are generally
found in different tissues and cellular compartments.
They are neurolysin (EC 3.4.24.16) [2,3] and thimet oli-
gopeptidase (TOP, EC 3.4.24.15) [4], exhibiting similar
substrate specificities and possessing a highly conserved
HEFGH metal binding motif [5,6]. They were originally
described as having 60% sequence identity, and distribu-
tion in the cytosol, endoplasmic reticulum, mitochondria
and nucleus of different mammalian tissues and tumor
cells [7-9]. Membrane-associated forms of these enzymes
have been described in corticotrophic tumor cells [10],
neuronal cell lines [11] and neurons [12,13] and the
secreted forms in neuronal cell line [14-16] cultures.
Both peptidases are known to hydrolyze in vitro various
bioactive peptides, including bradykinin (BK) [17], and
numerous reports have linked the enzymes to the metab-
olism of these peptides in vivo [18-23]. BK, generated
through the action of kallikreins on a precursor kininogen
substrate, induces inflammation, increased vascular per-
meability, stimulation of the endothelial isoform of nitric
oxide (NO) synthase, and vasodilation. Pathological con-
ditions, such as myocardial ischemia, hypertension and
cancer are deeply influenced by the kallikrein/kininogen/
kinin system. Evidence suggests that part of the cardiopro-
tective effects of specific inhibitors of the angiotensin I-
converting enzyme (ACE) and neutral endopeptidase
(NEP) is due to the enhanced BK activity [24,25]. Schriefer
et al. [26] demonstrated that inhibition of TOP precludes
degradation of endogenous BK and provides long-lasting
protection from myocardial ischemia/reperfusion injury.
TOP and neurolysin also contribute to BK metabolism in
the blood vessels [27].
The BK role on tumor-associated angiogenesis and tumor
growth has already been addressed [28]. BK stimulates
angiogenesis in a sponge granuloma model, synergisti-
cally with interleukin-1 [29]. BK has been implicated in
the enhancement of tumor growth via increased permea-
bility of the tumor neo-vasculature [30,31]. Tumor
growth and development of tumor-associated angiogen-
esis are suppressed in kininogen-deficient rats [32,33].
These evidences suggest that BK is a primary mediator of
tumor angiogenesis and, consequently, of tumor growth.
In the present work, we have characterized TOP and neu-
rolysin activities in conditioned media, lysate and mem-
brane preparations of B16F10-Nex2 melanoma cells.
Furthermore, we used in vivo experiments and in vitro
Matrigel angiogenesis assay, to determine the role of oli-
gopeptidases released by B16F10-Nex2 melanoma cells
on tumor growth and BK-dependent angiogenesis. We
suggest that locally produced NO could play a role in the
regulation of anti-kinin TOP activity.
Methods
Mice and cell lineages
Six- to eight-week-old female C57BL/6 mice were
obtained from the Center for Development of Experimen-
tal Models (CEDEME) animal facility, Federal University
of São Paulo (UNIFESP), and kept in isolators, with auto-
claved water and food. The animal experiments were car-Page 2 of 14
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Committee for Animal Experimentation.
The B16F10 murine melanoma cell line is syngeneic in
C57Bl/6 mice and was originally obtained from the Lud-
wig Institute for Cancer Research (São Paulo Branch). At
the Experimental Oncology Unit (UNONEX), we isolated
sublines from the original cell line with different pheno-
types. The melanotic subline Nex2 (B16F10-Nex2) is
characterized by low immunogenicity and moderate viru-
lence. It forms lethal subcutaneous tumours, with no
metastasis to the lung unless injected intravenously. The
melanoma cells and human umbilical vein endothelial
cells (HUVEC) were maintained in complete medium
consisting of RPMI 1640, pH 7.2, supplemented with 10
mM N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic
acid (HEPES), 24 mM sodium bicarbonate, 10% heat-
inactivated fetal calf serum (FCS) from Gibco (Minneapo-
lis, MN, USA) and 40 μg/mL gentamicin sulfate (Hipola-
bor Farmacêutica, Sabará, MG, Brazil).
Tumor cells growth and processing
B16F10-Nex2 cells were grown in 75-cm3 flasks (Costar
Corning, NY, USA) until 80–90% confluence. Spent 10%
FCS-containing RPMI medium from melanoma cultures
was replaced by serum-free RPMI medium (10 mL/flask)
after three washings with PBS (10 mL/wash), following
further incubation for 8 h. The culture supernatant fluid
was collected, centrifuged at 1,800 g for 5 min and con-
centrated 10-fold using an Amicon cell (Millipore, MA,
USA) with 12 kDa cut-off membrane and stirring with N2
positive pressure at 4°C. The concentrated culture
medium (referred to as the 'supernatant') was used for
measurements of enzymatic activity.
To prepare cell lysates and membranes, the cells were
incubated for 8 h in serum-free medium and re-sus-
pended in 50 mM Tris-HCl, pH 7.4. They were then lysed
by sonication at 40 Hz (4 cycles of 60 s). After removal of
the cell debris by centrifugation at 12,000 g for 5 min, the
supernatant was centrifuged at 100,000 g for 2 h. The
supernatant of this centrifugation represents the cell lysate
and the pellet, re-suspended in 50 mM Tris-HCl, pH 7.4,
represents the cell membrane preparation.
The protein content of samples was determined as previ-
ously described [34] using bovine serum albumin as
standard. The culture concentrated supernatants, cell
lysates and membrane preparations were used in proteo-
lytic assays, in the in vitro angiogenesis assay on Matrigel
and in Western blotting with anti-TOP and anti-neuro-
lysin antibodies.
B16F10-Nex2 cells were irradiated at 10,000 rad and the
Trypan Blue negative cells were used in the angiogenesis
assay.
Western blotting
For Western blotting of TOP and neurolysin, 10 μg of
B16F10-Nex2 fractions (supernatant, lysate and mem-
brane) were separated in 10% SDS-PAGE and then elec-
trophoretically transferred onto nitrocellulose membrane
(0.2 μm, Amersham Bioscience, England). Membranes
were incubated for 1 h in PBS and 5% dry skim milk. The
anti-TOP and anti-neurolysin antibodies (Proteimax, São
Paulo, Brazil) at 1:1000 were used as the primary anti-
body, and the secondary antibody was horse-radish per-
oxidase-conjugated goat anti-rabbit antibody in PBS and
1% dry skim milk. The blot was visualized using the ECL
detection system (Amersham Pharmacia Biotech).
In vitro angiogenesis assay on Matrigel
BD Matrigel™ Matrix (B&D Biosciences, Bedford, MA,
USA) was thawed on ice and then 15 μL per well was dis-
tributed in 96-well plates, and allowed to polymerize for
1 h at 37°C. HUVEC cells (5 × 103 cells/well) suspended
in 100 μL of RPMI medium supplemented with 0.2% of
FCS were added to each well in the presence of the follow-
ing inducers or inhibitors, isolated or combined: BK (1
μM), B16F10-Nex2 supernatant, membrane preparation
or lysate, rTOP (specific activity: 231 μM/min/mg pro-
tein), JA-2 (5 μM), NT (1 μM), Angiotensin-II (1 μM) or
CA-074 (100 nM). In the co-culture model consisting of
HUVEC cells and irradiated B16F10-Nex2 cells (5 × 103
cells/well), the tumor and endothelial cells were added
together to Matrigel after polymerization. The co-culture
assay was standardized with live irradiated melanoma
cells to prevent tumor growth.
The plates were incubated at 37°C for 18 h and then
images were captured at 8× magnification with a Sony
Cyber-shot camera coupled to a light inverted micro-
scope. The number of angiogenic structures (closed rings)
was counted from 4 different wells, and the average value
was determined for each sample. As a control of the assay
HUVEC cells were plated on Matrigel without any addi-
tion.
Peptides
FRET peptides derived from neurotensin (NT) and brady-
kinin (BK) were synthesized by the solid phase and classi-
cal solution methods of peptide synthesis [35,36] using o-
aminobenzoic acid (Abz) as fluorescent group and ethyl-
enediamino-2,4-dinitrophenyl (EDDnp) as fluorescence
quencher, attached respectively to the N- and C-terminal
groups of the peptides. All the obtained peptides were
purified by semi-preparative HPLC on an Econosil C-18
column. The molecular mass and purity of synthesizedPage 3 of 14
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mass spectrometry, using a TofSpec-E from Micromass,
Manchester, UK. Nonderivatized NT and BK peptides
were purchased from Sigma, St Louis, MO, USA.
Kinetic assays
Hydrolysis of the fluorogenic peptidyl substrates (approx.
20 μM) at 37°C in 50 mM Tris-HCl buffer, pH 7.4, was
followed by measuring the fluorescence at λem. = 420 nm
and λex. = 320 nm in a Hitachi F-2000 spectrofluorometer.
The 1-cm-path-length cuvette containing 1 ml of the sub-
strate solution was placed in a thermostatically controlled
cell compartment for 5 min before the samples were
added and the increase in fluorescence with time was con-
tinuously recorded for 5–10 min. The readings were con-
verted into moles of hydrolyzed substrate per minute
based on the fluorescence curves of standard peptide solu-
tions before and after total enzymatic hydrolysis. The con-
centration of the peptide solutions was obtained by
colorimetric determination of the 2, 4-dinitrophenyl
group (17,300 M-1.cm-1 extinction coefficient at 365 nm).
The sample concentration for initial rate determination
was chosen at a hydrolysis level less than 5% the substrate
present. Inhibitors were added to the reactions to deter-
mine the putative contribution of various proteases in the
cleavage of substrates using as control the inhibition by
the same inhibitors of the recombinant enzymes.
PMSF, E-64, o-phenanthrolin, Z-Pro-Prolinal, leupeptin,
captopril and S-nitroso-N-acetylpenicillamine (SNAP)
were purchased from Sigma (St Louis, MO, USA). Bestatin
was a gift from Kaethy B. Alves, UNIFESP, Brazil. The JA-2
inhibitor [37], originally from Ian Smith of the Baker
Heart Research Institute, Australia, was provided by
A.C.M. Camargo, Butantan Institute, Brazil. The specific
antibodies against TOP and neurolysin were purchased
from Proteimax (São Paulo, SP, Brazil). The results were
recorded as the percentage of residual activity relative to
control reactions run simultaneously in the absence of the
inhibitor.
Hydrolysis of neurotensin and bradykinin
The reactions of NT (pELYENKPRRPYIL) or BK (RPPGF-
SPFR) (20 μM each) with mammalian recombinant
enzymes and B16F10-Nex2 supernatant, with or without
inhibitors, were carried out for 1 h at 37°C in 50 mM Tris-
HCl buffer, pH 7.4. Each aliquot of reaction products was
then analyzed by HPLC, monitoring the absorbance at
220 nm.
Determination of cleaved peptide bonds
The sites of peptide cleavage were identified by isolation
of the fragments in analytical HPLC. Fractions were mon-
itored by UV absorbance at 220 nm and fluorescence
readings at λem. = 420 nm and λex. = 320 nm. The retention
times of the fragments produced were compared with
authentic synthetic peptide sequences and molecular
mass determination by MALDI-TOF (TofSpec-E, Micro-
mass) mass spectrometry.
Cloning and expression of recombinant enzymes
TOP and neurolysin genes were cloned from B16F10-
Nex2 melanoma cells and expressed as indicated below.
The expression vectors pHis3-TOP and pHis3-Neurolysin
were constructed by insertion of the genes into pHis3
plasmid, a modified pET vector. The cDNAs encoding the
full length murine melanoma TOP and neurolysin were
reverse-transcribed from total B16F10-Nex2 melanoma
RNA with superscript II-reverse transcriptase (Gibco BRL).
The PCR mixture consisted of 1/10 of reaction-cDNA, 200
μM deoxynucleoside triphosphates, 2 mM MgCl2, 50 mM
KCl, 20 mM Tris-HCl (pH 8,4), 1 U taq DNA polymerase
and 50 pmoles of each of the primers: 5'-
ATGAAGCCCCCCGCAG-3' and 5'-TCAGCACGCAG-
GCGCCTC-3' for TOP, and 5'-ATGATCACCCTGTGCC-3'
and 5'-TTACGAAGCATTCAGGCC-3' for neurolysin. The
PCR temperature cycle was 94°C for 3 min, followed by
35 cycles of 94°C for 1 min, 60°C for 1 min, 72°C for 3
min, and finally holding for 10 min at 72°C. The ampli-
fied fragments were recovered from 1% Agarose gel using
BIOCLEAN for purification of DNA bands (BIOTOOLS,
Brazil) and cloned on pGEM-T easy vector (PROMEGA,
Madison, USA). The cloned gene fragment was excised
from the plasmid by digestion with EcoRI (Invitrogen,
Carlsbad, CA, USA) and ligated into the EcoRI site of
pHis3 vector. The resulting constructs were verified by
restriction enzyme mapping and DNA sequencing. The
gene sequences were translated and compared with
mouse TOP and neurolysin published sequences.
For expression, E. coli BL21 (DE3) pLysS was transformed
by heat shock in expression vectors and these were grown
at 37°C for 16 h, with shaking, in Luria-Bertani medium,
with ampicillin (100 μg/ml) and chloramphenicol (50
μg/ml). The transformed bacteria were re-inoculated in
fresh medium and grown with antibiotic selection to A600
= 0.6, and the expression of the recombinant protein was
induced with 1 mM isopropyl β-D-thiogalactoside
(IPTG), for 4 h. Bacterial cultures were centrifuged at
1,075 g for 20 min at 4°C, re-suspended in 50 mM Tris-
HCl, pH 7.4 and then lysed by sonication at 40 Hz (4
cycles of 60 s). After removal of the bacterial debris by cen-
trifugation, the supernatants were incubated with Ni-NTA
(Nickel-nitrilotriacetic acid) Agarose (Qiagen, Hilden,
Germany) equilibrated in Buffer A (20 mM Tris-HCl, pH
8.5, 100 mM KCl, 20 mM imidazole, 10 mM 2-mercap-
toethanol, 10% [v/v] glycerol) for 3 h at 4°C with shak-
ing. After washing with 10 volumes of Buffer A,
recombinant protein was eluted from the column with 2
volumes of Buffer C (20 mM Tris-HCl, pH 8.5, 100 mMPage 4 of 14
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10% [v/v] glycerol). Recombinant protein was desalted in
a PD-10 column (Amersham Pharmacia Biotech), ana-
lyzed by polyacrylamide gel electrophoresis after staining
with Coomassie blue R-250 (Bio-Rad Laboratories, Rich-
mond, CA, U.S.A.) and used in the assays below.
Cell proliferation assay
B16F10-Nex2, 5 × 103 cells per well, was cultivated in 96-
well plates and, after cell attachment for 6 h, incubated for
12, 24 and 48 h in the presence or absence of JA-2 (3 μM)
and/or bestatin (50 μM) inhibitors. The cell proliferation
was measured using the Cell Proliferation Kit I (MTT)
(Boehringer Mannheim), an MTT-based colorimetric
assay for quantification of cell proliferation and viability.
Readings were made in a plate reader at 570 nm.
In vivo grafting of tumor cells
For in vivo experiments, C57BL/6 mice (4–5 animals per
group) were inoculated subcutaneously on the right flank
with a suspension containing 5 × 104 viable cells in 0.1 mL
of serum-free RPMI medium in the presence or absence of
active or inactive rTOP (8 μg protein and specific activity
of 231 μM/min/mg protein). Tumor growth was followed
by measuring its volume with a caliper three times a week,
and also scoring the survival of challenged animals. The
tumor volume was calculated using the formula: V = 0.52
× D12 × D3, where D1 and D3 are the short and long tumor
diameters, respectively. Maximal volumes of 3–4 cm3
were allowed before sacrifice. Survivals of mice were
scored and statistically compared.
Statistical analysis
The data are represented as means ± SE. Statistical signifi-
cance was determined by the Student's t test. All experi-
ments were conducted two or more times. Reproducible
results were obtained and representative data are shown.
The survival plots of animals challenged with tumor cells
and injected simultaneously with active or inactive rTOP
were analyzed by Kaplan-Meier log rank test.
Results
Effect of B16F10-Nex2 melanoma cells on angiogenesis
The effect of B16F10-Nex2 melanoma cells on endothelial
cell angiogenesis was examined in sets of co-culture on
Matrigel, as an angiogenesis assay. HUVEC endothelial
cells were plated on Matrigel with BK, irradiated B16F10-
Nex2 cells or B16F10-Nex2 supernatant, lysate or mem-
brane preparation (Fig. 1). The growth of HUVECs on
Matrigel with 0.2% fetal calf serum led to the formation of
closed intercellular compartments arising from endothe-
lial cell sprouting (pro-angiogenic structure) independent
of any other factor. Addition of BK to the incubation mix-
ture at 1 μM stimulated formation of these structures
more than 2-fold. The co-culture of irradiated melanoma
and endothelial cells increased the number of pro-ang-
iogenic structures to the same level as in BK-treated
HUVECs. The same occurred with the B16F10-Nex2 mem-
brane preparation and lysate. In contrast, B16F10-Nex2
supernatant exerts a clear negative effect on angiogenesis
compared to the control.
To characterize the angiogenesis inhibitory factors
secreted in the supernatant of B16F10-Nex2 cells, we
tested the effect of JA-2, an inhibitor of thimet oligopepti-
dase. This enzyme is able to hydrolyze BK, a known pro-
angiogenic factor. We observed that JA-2 reversed the neg-
ative effect promoted by the melanoma supernatant, but
did not affect the basal formation of pro-angiogenic struc-
tures (Fig. 2).
Effect of BK and B16F10-Nex2 tumor cells on pro-angiogenic closed structures formed by sprouting of endothelial cellsFigure 1
Effect of BK and B16F10-Nex2 tumor cells on pro-
angiogenic closed structures formed by sprouting of 
endothelial cells. HUVECs were plated on Matrigel in 
medium supplemented with 0.2% of FCS in the presence of 
BK, B16F10-Nex2 supernatant, cell membrane or lysate and 
irradiated B16F10-Nex2 whole cells. The number of pro-ang-
iogenic structures was counted after 18 h. One representa-
tive picture of four different treatments is shown with the 
respective counts. * p < 0.005 vs control; ** p < 0.0005 vs 
control.
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To further address the enzymatic activity of B16F10-Nex2
supernatant, FRET peptides derived from NT and BK, pre-
viously employed to determine the specificity of recom-
binant TOP and neurolysin oligopeptidases [38,39], were
used. The melanoma supernatant was able to cleave all
the assayed substrates, except Abz-GFPPFRQ-EDDnp and
Abz-rRL-EDDnp (Table 1), which were also resistant to
recombinant TOP and neurolysin. The fluorogenic sub-
strate Abz-rRL-EDDnp was previously used to identify
neprilisin oligopeptidase [40], which was not detected in
the B16F10-Nex2 supernatant. However, the conditioned
medium cleaved preferentially Abz-GFSPFRQ-EDDnp,
which is a very susceptible substrate for TOP.
HPLC analyses of Abz-GFSPFR-EDDnp and Abz-GFSP-
FRQ-EDDnp degradation products by B16F10-Nex2
supernatant and rTOP are shown in Figure 3. As previ-
ously described for TOP and neurolysin [39], Abz-
GFSPFR-EDDnp was cleaved at Phe-Ser bond, but the
presence of glutamine in Abz-GFSPFRQ-EDDnp shifted
the cleavage to Pro-Phe bond (Fig. 3A and 3B). Melanoma
supernatant hydrolyzed these substrates as the recom-
binant TOP and neurolysin do (Fig. 3C and 3D), indicat-
ing that the melanoma peptidase activities could be
related to these enzymes.
Inhibition of the peptidase activity
The effects of the peptidase inhibitors on the hydrolysis of
Abz-GFSPFRQ-EDDnp by B16F10-Nex2 supernatant,
recombinant TOP and neurolysin are shown in Table 2.
PMSF (0.1 mM), E-64 (0.1 mM), Z-Pro-Prolinal (1 μM),
leupeptin (0.2 mM) and captopril (20 μM) have no
effects. Pro-Ile (1 mM), a specific inhibitor of neurolysin
[41], inhibited by ~40% the B16F10-Nex2 supernatant
enzymes and ~50% the recombinant neurolysin, but does
not inhibit TOP. o-Phenanthrolin (4 mM) and JA-2 (3
μM) were the most effective inhibitors of both, the stand-
ard recombinant enzymes and of the B16F10-Nex2 super-
natant. o-Phenanthrolin is a specific inhibitor of metallo-
proteases and JA-2 was described as a specific inhibitor of
TOP [37], but it also inhibits neurolysin as we have shown
here. The activities of B16F10-Nex2 supernatant on fluor-
HPLC analysis of FRET peptides degradation by the B16F10-Nex2 supernatantFigure 3
HPLC analysis of FRET peptides degradation by the 
B16F10-Nex2 supernatant. Abz-GFSPFR-EDDnp (A, C) 
or Abz-GFSPFRQ-EDDnp (B, D) were incubated with 
recombinant oligopeptidase TOP (A, B), or B16F10-Nex2 
supernatant (C, D) in 50 mM Tris-HCl pH 7.4 at 37°C. Reac-
tion products were separated by HPLC and were identified 
by mass spectrometry. Chromatograms developed by fluo-
rescence detection at λem. = 420 nm and λex. = 320 nm.
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Effect of JA-2 on in vitro Matrigel angiogenesis assayFigure 2
Effect of JA-2 on in vitro Matrigel angiogenesis assay. 
HUVECs were plated on Matrigel in medium supplemented 
with 0.2% of FCS in the presence of BK, B16F10-Nex2 super-
natant and JA-2 (thimet oligopeptidase inhibitor). The 
number of pro-angiogenic structures was counted after 18 h. 
* p < 0.05 vs control; ** p < 0.005 vs control.
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Table 1: Proteolytic activity of B16F10-Nex2 supernatant and 
recombinant enzymes on FRET peptides
Abz-peptidyl-
EDDnp
Specific activity (nmoles/min/mg protein)
B16F10-Nex2 rTOP rNeurolysin
GFSPFRQ 2.7 ± 0.6 100 ± 9.8 5.5 ± 1.0
GFSPFR 0.6 ± 0.1 21 ± 4.2 4.4 ± 0.5
GFSIFRQ 0.6 ± 0.1 14 ± 4.4 1.6 ± 0.2
GFPPFRQ 0 0 0
NKPRRPQ 0.4 ± 0.4 29 ± 3.3 58 ± 8.3
RPPGFSPFRQ 1.8 ± 0.1 51 ± 5.5 8.8 ± 0.7
rRL 0 0 0
B16F10-Nex2 supernatant and recombinant enzymes were incubated 
with fluorogenic substrates (20 μM) in 50 mM Tris-HCl, pH 7.4 at 
37°C. Hydrolysis was followed by measuring the fluorescence at λem. 
= 420 nm and λex. = 320 nm. Results are expressed as means ± SD.Page 6 of 14
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Molecular Cancer 2007, 6:44 http://www.molecular-cancer.com/content/6/1/44ogenic quenched substrates are shown in Table 1, which
were also totally inhibited by o-phenanthrolin and JA-2.
Hydrolysis of neurotensin and bradykinin
NT represents the only known peptide differentially
cleaved by TOP and neurolysin, therefore it is a very useful
reagent to distinguish these peptidase activities. TOP
hydrolyzes the Arg-Arg bond, producing NT1–8 and NT9–13
whereas neurolysin cleaves the Pro-Tyr bond, producing
NT1–10 and NT11–13. Incubation of NT with melanoma
supernatant resulted in the generation of NT1–8 and NT1–
10 (Fig. 4D), the same N-terminal fragments generated
respectively by cleavage of NT by TOP and neurolysin
(Fig. 4A and 4B), that were identified by mass spectrome-
try. The same assay was performed in the presence of bes-
tatin (50 μM), an aminopeptidase inhibitor. In previous
assays, bestatin was able to completely inhibit the super-
natant peptidase activity using Phe-MCA as substrate,
indicating the presence of an aminopeptidase in the
melanoma supernatant (data not shown). In the presence
of bestatin, the fragment of NT10–13 (Fig. 5C) was detected
as confirmed by mass spectrometry. The aminopeptidase
presents in the B16F10-Nex2 supernatant was responsible
for cleaving the NT C-terminal fragments. The fragment
NT9–13 was not observed in the HPLC due to the presence
of bestatin at exactly the same elution time, as shown in
Figure 5A. Bestatin, as expected, was unable to modify the
HPLC profile of TOP and neurolysin (Fig. 5A and 5B).
The cleavage of BK at the Phe-Ser bond by TOP and neu-
rolysin was previously described [42]. The B16F10-Nex2
supernatant cleaved BK at the same site, with the corre-
sponding fragments being identified by mass spectrome-
try (Fig. 6B). The HPLC of fragments arisen from BK
hydrolysis by recombinant TOP was the control shown in
Figure 6A.
Cloning of TOP and neurolysin from B16F10-Nex2 
melanoma cells
Both melanoma enzyme cDNAs were cloned, confirming
the presence of TOP and neurolysin in melanoma cells,
and the gene and translated protein sequences were com-
pared to the mouse sequences (data not shown).
The cDNA sequence of TOP from melanoma showed a
single nucleotide change by comparing with the mouse
enzyme. The point mutation on adenine 300 to guanine
was not able to cause alterations in the amino acid
sequence.
The complete sequencing of neurolysin cDNA from
melanoma showed three modifications in relation to the
mouse gene: thymine 666 to cytosine, thymine 1268 to
cytosine and thymine 1316 to cytosine. Only two changes
promoted substitutions in the amino acid sequence: Val
423 to Ala and Leu 439 to Pro. These changes did not
seem to affect the active site of the enzyme and did not
include amino acids described as important for enzyme
activity [43,44].
Peptidase activity in the culture supernatant, lysate and 
membrane preparation of B16F10-Nex2 cell line
The oligopeptidase activities in the culture supernatant,
lysate and membrane preparations of B16F10-Nex2
melanoma cells were compared. The melanoma cells dis-
HPLC analysis of neurotensin (NT) degradation by B16F10-Nex2 supernatantFigure 4
HPLC analysis of neurotensin (NT) degradation by 
B16F10-Nex2 supernatant. Neurotensin (20 μM) was 
incubated for 1 h at 37°C with recombinant TOP (A), neuro-
lysin (B) or B16F10-Nex2 supernatant (D) in 50 mM Tris-
HCl, pH 7.4. The reaction products were separated by 
HPLC. HPLC profile of melanoma supernatant without NT is 
shown on panel C. The neurotensin fragments were deter-
mined by mass spectrometry.
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Table 2: Effect of inhibitors on the hydrolysis of Abz-GFSPFRQ-
EDDnp by B16F10-Nex2 supernatant and recombinant TOP and 
Neurolysin
Inhibitors Relative hydrolysis (%)1
B16F10-Nex2 rTOP rNeurolysin
Control (no inhibitor) 100 100 100
o-phenanthrolin (4 mM) 0 0 0
JA-2 (3 μM) 2.6 ± 2.1 0.6 ± 1.2 1 ± 1
Pro-Ile (1 mM) 60 ± 6 87 ± 5 52 ± 4
PMSF (0.1 mM) 94 ± 6 91 ± 4 93 ± 4
E64 (0.1 mM) 88 ± 3 98 ± 2 99 ± 2
Leupeptin (0.2 mM) 81 ± 6 96 ± 2 96 ± 4
Z-Pro-Prolinal (1 μM) 93 ± 1 88 ± 3 92 ± 4
Captopril (20 μM) 92 ± 3 97 ± 2 98 ± 2
1100% hydrolysis represents the cleavage of 20 μM of Abz-GFSPFRQ-
EDDnp by B16F10-Nex2 supernatant and recombinant enzymes 
during 5 min at 37°C in 50 mM Tris-HCl, pH 7.4. The values are 
means of three independent experiments.Page 7 of 14
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Molecular Cancer 2007, 6:44 http://www.molecular-cancer.com/content/6/1/44play the greatest oligopeptidase activity in the lysate as
shown by hydrolysis of Abz-GFSPFRQ-EDDnp in Table 3.
The activity in the supernatant is 10-fold less that of the
lysate, when the results are expressed in enzyme activity
per cell. If the assay is standardized by specific activity, the
supernatant and lysate values were 1.39 and 3.22 μM/min
per mg of protein, respectively, because the protein con-
tent in the lysate is approximately 4-fold that in the super-
natant. The total activity based on the volume of the
fractions showed that the lysate had much more oli-
gopeptidase activity than the supernatant. The activity in
the membrane fraction was very low, but the protein was
clearly detected by Western blotting (data not shown). To
demonstrate the expression levels of TOP and neurolysin
in melanoma cells, B16F10-Nex2 fractions were submit-
ted to immunoblotting, using specific antibodies against
these two oligopeptidases. We detected TOP expression in
the supernatant, lysate and membrane preparations of
B16F10-Nex2 melanoma cells (data not shown). Neuro-
lysin expression was not detected using this method. The
specific anti-TOP antibody inhibited 80% of the B16F10-
Nex2 catalytic activity, using the FRET peptide Abz-GFSP-
FRQ-EDDnp, whereas the anti-neurolysin antibody
inhibited only 20% of the melanoma enzyme activity
(Table 3).
Tumor cell proliferation assay
A proliferation assay in vitro was carried out in the pres-
ence of JA-2 and bestatin and the results are shown in Fig-
ure 7. JA-2 and bestatin decreased B16F10-Nex2 cell
growth 50% and 56% respectively in 48 h. A synergistic
inhibitory effect (88% inhibition of proliferation in 48 h)
was observed when both inhibitors were added together
in the melanoma culture.
Effect of TOP on tumor development in vivo
To assess the effect of TOP on the tumor development in
vivo, tumor cells were injected subcutaneously in syn-
geneic mice together with active or inactive rTOP at con-
HPLC analysis of BK degradation by B16F10-Nex2 superna-tantFigure 6
HPLC analysis of BK degradation by B16F10-Nex2 
supernatant. BK (20 μM) was incubated for 1 h at 37°C 
with recombinant TOP (A) or B16F10-Nex2 supernatant (B) 
in 50 mM Tris-HCl, pH 7.4. The reaction products were sep-
arated by HPLC. Bradykinin fragments were determined by 
mass spectrometry.
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HPLC analysis of neurotensin (NT) degradation by B16F10-Nex2 supernatant in the presence of bestatinFigure 5
HPLC analysis of neurotensin (NT) degradation by 
B16F10-Nex2 supernatant in the presence of besta-
tin. Neurotensin (20 μM) was incubated for 1 h at 37°C with 
recombinant TOP (A), neurolysin (B) or B16F10-Nex2 
supernatant (D) in the presence of bestatin in 50 mM Tris-
HCl, pH 7.4. The reaction products were separated by 
HPLC. HPLC profile of melanoma supernatant in the pres-
ence of bestatin without NT is shown on panel C. The neu-
rotensin fragments were determined by mass spectrometry.
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Molecular Cancer 2007, 6:44 http://www.molecular-cancer.com/content/6/1/44centrations that did not affect the growth of tumor cells in
vitro.
Tumor cell implantation in the presence of 8 μg of active
rTOP (specific activity: 231 μM/min per mg) was followed
by delayed tumor growth and prolonged survival of
injected mice (p = 0.034) (Fig. 8A and 8B). In contrast
there was no significant difference (p = 0.32) in the tumor
development when B16F10-Nex2 cells were injected in
the presence of inactive rTOP (Fig. 8C and 8D).
Effect of TOP in angiogenesis assay on Matrigel
We examined the ability of rTOP to stimulate pro-ang-
iogenic structures by HUVECs cultured on Matrigel. These
structures arise from sprouting of endothelial cells and
formation of closed intercellular compartments that can
be quantified. As shown in Figure 1, BK stimulated the for-
mation of pro-angiogenic structures >2-fold. TOP alone
was able to inhibit endothelial cell extensions and reverse
the angiogenic stimulus promoted by BK (Fig. 9). Further,
NT and angiotensin II (A-II), other peptides hydrolyzed
by TOP, also stimulated angiogenesis.
Inhibition of rTOP activity by SNAP
To verify the possible inhibition of rTOP by nitric oxide,
which could suggest a way of controlling the activity of the
endo-oligopeptidase, we carried out a kinetic assay with
the recombinant enzyme and S-nitroso-N-acetylpenicilla-
mine (SNAP), as NO donor. SNAP (1 mM to 100 μM) was
incubated with rTOP for 10 minutes and then the fluoro-
genic substrate Abz-GFSPFRQ-EDDnp was added to the
reaction. The result in Table 4 shows that SNAP inhibited
TOP hydrolytic activity using substrate Abz-GFSPFRQ-
EDDnp, in a dose-dependent manner, but not time-
dependent kinetics (data not shown). At 100 μM, SNAP
was unable to inhibit TOP. Addition of 1, 4-dithiothreitol
Effect of active and inactive rTOP on tumor cell development and anim l survival after subcutaneous implantation of B16F10-Nex2 melanoma cellsFigure 8
Effect of active and inactive rTOP on tumor cell 
development and animal survival after subcutaneous 
implantation of B16F10-Nex2 melanoma cells. 5 × 104 
viable cells were injected subcutaneously with 8 μg of active 
rTOP (A, B, open circle), inactive rTOP (C, D, open circle), 
and PBS (control, solid circle) in C57Bl/6 mice (4–5 animals 
per group). The tumor volume was measured every 2–3 days 
and a maximal volume of 3 cm3 was allowed before sacrifice. 
(B, D), tumor volume of individual animals; (A, C), survival 
plots. Statistical analysis of survivals was performed using 
Kaplan-Meier test.
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Table 3: Oligopeptidase activities in the culture supernatant, cell lysate and membrane fraction of B16F10-Nex2 cells
Cell fraction Specific activity (μM/min per mg) Activity per cell (pM/min per 103 cells) Total activity (μM/min)
Supernatant 1.39 ± 0.24 36 ± 16 3.36 ± 0.15
Lysate 3.22 ± 0.96 326 ± 15 31.56 ± 0.16
Lysate + Anti-TOP Ab 0.64 ± 0.19 65 ± 5 6.31 ± 0.03
Lysate + Anti-Neurolysin Ab 2.58 ± 0.77 261 ± 5 25.25 ± 0.13
Membrane* < 0.01 3 ± 0.5 0.2 ± 0.01
Culture supernatant, cell lysate and membrane preparation of B16F10-Nex2 cells were incubated with the fluorogenic substrate Abz-GFSPFRQ-
EDDnp (20 μM) in 50 mM Tris-HCl, pH 7.4 at 37°C. Enzyme activity was followed by measuring the fluorescence at λem. = 420 nm and λex. = 320 
nm. Results are expressed as means ± SD. Ab= antibodies, used at 1:300.
*Although the activity of TOP in the membrane was low, the protein was clearly detected by Western blotting with anti-TOP antibody.
B16F10-Nex2 proliferation assay in the presence of JA-2 and/or bestatin inhibitorsFigure 7
B16F10-Nex2 proliferation assay in the presence of 
JA-2 and/or bestatin inhibitors. 5 × 103 B16F10-Nex2 
cells were cultivated in 96-well plates, incubated for 12, 24 
and 48 h with JA-2 (3 μM) and/or bestatin (50 μM) inhibitors, 
and the cell proliferation was measured using MTT in com-
parison with Controls. *p < 0.05.
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Molecular Cancer 2007, 6:44 http://www.molecular-cancer.com/content/6/1/44(DTT) in the assay before the fluorogenic substrate pre-
vented TOP inhibition by SNAP.
Discussion
We describe in the present work the stimulating effect on
angiogenesis of irradiated melanoma B16F10-Nex2
tumor cells using HUVEC on Matrigel substrate. A
melanoma cell lysate and membrane preparation showed
the same effect of whole irradiated tumor cells, suggesting
a distribution of pro-angiogenic factors in both mem-
brane and cytoplasm of the tumor cells. In contrast,
B16F10-Nex2 conditioned medium inhibited endothelial
cell sprouting and the formation of pro-angiogenic struc-
tures. The negative effect on angiogenesis was reversed by
the thimet oligopeptidase inhibitor JA-2, suggesting the
anti-angiogenic role of this or a similar secreted oli-
gopeptidase into the melanoma culture supernatant.
The presence of TOP and neurolysin in melanoma cells
and culture supernatants was confirmed by hydrolytic
assays and by cloning and sequencing the corresponding
cDNAs from B16F10-Nex2 cells. The hydrolysis of NT, BK
and FRET peptides were consistent with the presence of
Zn-dependent oligopeptidases with a catalytic activity
similar to that of both TOP and neurolysin. In addition,
the enzymes of the melanoma supernatant hydrolyzed the
substrate Abz-GFSPFRQ-EDDnp at the Pro-Phe bond as
described for TOP and neurolysin, indicating that the
melanoma activity had the same specificity as of the
recombinant mouse enzymes (Figs 3C and 3D).
The complete inhibition of melanoma peptidase by o-
phenanthrolin as well as by JA-2, and the partial inhibi-
tion by Pro-Ile give support to the functional similarity of
melanoma enzymes with the oligopeptidases TOP and
neurolysin. The absence of inhibition of peptidase activity
by PMSF, E-64, Z-Pro-Prolinal, leupeptin and captopril
excludes the presence of other peptidase classes eventually
responsible for the cleavage of Abz-GFSPFRQ-EDDnp, the
substrate used in these assays. The generation of NT9–13
and NT10–13 in the presence of bestatin suggested that an
aminopeptidase was the most likely enzyme responsible
for degradation of the C-terminal fragment of NT.
The cDNA sequencing of melanoma enzymes showed few
mutations in comparison with the mouse counterparts.
The only modification found in the melanoma TOP gene
sequence did not cause an alteration in the amino acid
sequence. The melanoma neurolysin gene showed three
modifications in relation to mouse gene sequence, but
only two changes promoted substitutions in the amino
acid sequence away from the conserved Zn-binding cata-
lytic site (HEFGH) or from other amino acids described as
important to enzyme activity [43,44].
We show here that significant TOP and neurolysin-like
activities can be detected in conditioned media, lysate and
membrane preparations from melanoma cells. The oli-
gopeptidase activity per cell was 10-fold greater in the
lysate than supernatant. The activity in the cell membrane
preparation was scarce. When the assay was normalized
by specific activity, the supernatant and lysate values were
similar, since the protein content in the lysate is approxi-
mately 4-fold that in the supernatant. Using specific anti-
bodies against the studied oligopeptidases, we showed
that TOP activity in melanoma cells is significantly greater
than that of neurolysin. TOP expression as detected by
immunoblotting was prominent in the supernatant,
lysate and membrane fraction of B16F10-Nex2 cells.
The importance of the oligopeptidases for melanoma cells
in vitro was assessed by proliferation assay in the presence
of JA-2 and bestatin. We observed a decreased B16F10-
Nex2 cell proliferation in the presence of JA-2, bestatin
and a greater inhibition with both. Presumably both
Table 4: Effect of the NO donor SNAP on the hydrolysis of Abz-
GFSPFRQ-EDDnp by rTOP
SNAP Hydrolysis (%)1
Control (no inhibitor) 100
1 mM 38 ± 3
500 μM 50 ± 3
250 μM 83 ± 4
100 μM 98 ± 2
1 mM + DTT 0.5 mM 100 ± 1
1100% hydrolysis represents the cleavage of 20 μM of Abz-GFSPFRQ-
EDDnp by rTOP during 5 min at 37°C in 50 mM Tris-HCl, pH 7.4.
Effect of rTOP on in vitro Matrigel angiogenesis assayFigure 9
Effect of rTOP on in vitro Matrigel angiogenesis 
assay. HUVECs were plated on Matrigel in medium supple-
mented with 0.2% of FCS in the presence of BK (1 μM), 
rTOP (specific activity: 231 μM/min/mg), BK+ rTOP, NT (1 
μM) and A-II (1 μM). The number of pro-angiogenic struc-
tures was counted after 18 h. * p < 0.05 vs control.
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Molecular Cancer 2007, 6:44 http://www.molecular-cancer.com/content/6/1/44inhibitors may act intracellularly, inhibiting oligopepti-
dases and aminopeptidases that are essential for
melanoma cells. The secretion of both enzymes, TOP and
neurolysin, might, however, influence tumor growth in
vivo by affecting angiogenesis. Mice injected with active
rTOP at a concentration that was not toxic in vitro,
showed a delay in tumor development and increased sur-
vival of animals compared with mice challenged with
tumor cells and inactive rTOP, indicating that the active
enzyme and not only the protein was necessary for this
effect. A possible target of rTOP activity in the tumor
microenvironment could be kinins stimulating angiogen-
esis.
Tumors require an adequate supply of oxygen, metabo-
lites and an effective way to remove waste products [45].
The generation of new blood vessels for tumor blood sup-
ply is thus a rate-limiting step in tumor progression, being
a prerequisite for the rapid clonal expansion associated
with the formation of macroscopic tumors [46]. Experi-
mental data suggest that the angiogenic stimulation
[46,47] is activated during the early stages of tumour
development [48-51]. During development of cutaneous
melanoma in humans a similar stage-specific stimulation
is also evident [52]. Tumors appear to activate the ang-
iogenic switch by changing the balance of angiogenesis
inducers and counteracting inhibitors, so that tumor neo-
vascularization and consequent growth depends on how
heavily the balance tips towards angiogenesis [53,54].
One strategy for shifting the balance involves proteases
that can control the bioavailability of angiogenic activa-
tors and inhibitors.
A prototype of pro-angiogenic molecule is bradykinin.
Evidence suggests that BK may be one of the primary
mediators responsible for tumor angiogenesis and, conse-
quently, of tumor growth [28-33]. It is well known that
endothelial cells can synthesize and secrete tissue kal-
likrein [55]. Schmaier et al [56] have also shown the
expression of high molecular weight kininogen in human
umbilical vein endothelial cells (HUVEC). The generation
of the vasoactive peptide bradykinin from HUVEC-bound
high molecular weight kininogen is also known [57].
Therefore, endothelial cells, particularly those used in the
present study (HUVEC) do produce kininogen and kal-
likrein and generate BK. Such functional activities of
endothelial cells are stimulated in Matrigel. The inhibitory
effect of active rTOP inoculated with tumor cells, could
well involve the hydrolysis of bradykinin, shifting the bal-
ance of angiogenic/anti-antiangiogenic factors at an early
stage of tumor implantation. In agreement with this we
have shown in an angiogenesis assay with HUVEC on
Matrigel that rTOP was able to reverse the angiogenic
stimulation promoted by BK. Similarly to BK, NT and A-
II, two peptides that are hydrolyzed by TOP, were able to
stimulate the endothelial cell sprouting. These peptides
are further examples of positive modulators of the ang-
iogenic process.
The results suggest that TOP affects angiogenesis in vitro
and in vivo, at concentrations that did not inhibit
B16F10-Nex2 tumor cells directly. The secretion of TOP
by tumor cells would therefore favor an anti-angiogenic
response in balance with the pro-angiogenic stimuli by
other tumor proteases expressed for instance at the cell
surface and released in the medium. We incubated
HUVEC cells with CA-074, a cathepsin B inhibitor, in the
Matrigel angiogenesis assay and showed stimulation of
angiogenesis. The same inhibitor enhanced the pro-ang-
iogenic effect induced by B16F10-Nex2 lysate, tumor cell
membrane, and in the co-culture of B16F10-Nex2 with
HUVEC cells (data not shown). References to the role of
cathepsin B on tumor angiogenesis are contradictory. In
human tumors, there is evidence of a positive correlation
between the level of cathepsin B and angiogenesis [58],
and the inhibition of cathepsin B expression was associ-
ated with angiogenesis suppression [59]. In contrast, the
generation of endostatin by cathepsin B could block the
angiogenesis in many tumor systems [60]. The role of
cathepsins in melanoma requires additional studies in
face of the multienzymatic complex of the tumor micro-
environment. Clearly, in the in vitro Matrigel invasion
assays, cathepsins B and L increase the angiogenesis-inde-
pendent invasive capacity of tumor cells [61]. We
described a more invasive B16F10 clone (Nex2B) as com-
pared to a less invasive one (2D), though with a greater
capacity of lung colonization than 2B, based on the extra-
cellular rather than intracellular accumulation of cathep-
sins B, D, and L [1]. Nevertheless, an intracellular role for
cathepsin B in matrix degradation has been identified
[62], and also, three forms of extracellularly active cathe-
psin B and two forms of active cathepsin L have been
described in the highly invasive melanoma cell line MV3
[63]. These isoforms add to the complexity of the system
and demand a careful study to unravel their role on tumor
growth.
An additional control of angiogenesis and tumor growth
may exist based on the local release of NO. Kashiwagi et
al. [64] using intravital microscopy demonstrated in a B16
murine melanoma model that eNOS from vascular
endothelial cells is the predominant generator of NO. NO
released by endothelial cells could be an inhibitory ligand
of TOP activity. The inhibition of enzymes by nitric oxide
has been demonstrated in the cysteine proteases [65-67],
but not metallo-proteases. TOP and dipeptidylpeptidase
IV (DPP IV) were not inhibited by the NO donors sodium
nitroprusside(SNP) and 3-morpholinosydnoimine (SIN-
1) in the 1–100 μM range [68]. Both compounds, how-
ever, were shown to release peroxynitrite, a reactive nitro-Page 11 of 14
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Molecular Cancer 2007, 6:44 http://www.molecular-cancer.com/content/6/1/44gen species that primarily can nitrate tyrosine residues
[69]. Site-directed mutation of Tyr residues at positions
612 and 613 in TOP and neurolysin, respectively, strongly
reduced kcat/KM for both enzymes [70].
Nitrosothiols, which may act as NO reservoirs, could nit-
rosate cysteine residues [71], such as those that play an
important role in TOP activity [72]. Presently, we exposed
rTOP to SNAP a nitrosothiol, and the activity of the
enzyme was inhibited in a concentration-dependent man-
ner (250 μM to 1 mM range). Such inhibition was abol-
ished in the presence of DTT. This result should be
considered in the perspective of a tumor microenviron-
ment with hydrophobic niches that may increase the effi-
ciency of NO-based regulatory reactions [73], potentially
influencing angiogenesis and tumor growth.
Conclusion
The present work describes TOP and neurolysin oli-
gopeptidases in B16F10-Nex2 melanoma cells and shows
the importance of these enzymes for tumor proliferation
in vitro and in vivo. Recombinant TOP protected mice
against the subcutaneous challenge with murine
melanoma cells. The results suggest that secreted thimet
oligopeptidase in tumor cells and bradykinin are two
antagonist factors that may regulate or trigger the ang-
iogenic switch essential for melanoma growth. A regula-
tory role of NO or S-nitrosothiols on TOP activity is
suggested. Together with endogenous inhibitors, endo-
oligopeptidases secreted by tumor cells can also regulate
angiogenesis and might also be studied, in adequate pro-
tocols, as potential anti-tumor agents.
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